Pune, India -- (SBWIRE) -- 06/01/2018 -- Europe injectable drug delivery market is expected to USD 369,668.94 million by 2025, from USD 122,906.09 million in 2017 growing at a CAGR of 12.8% in the forecast period 2018 to 2025

Ask for Free Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=europe-injectable-drug-delivery-market

The market is further segmented into:
- Type
- Usage Pattern
- End-User
- Mode of Administration
- Distribution Channel
- Application
- Geography

The Europe injectable drug delivery market is segmented on of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.

The Europe injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 83.4% market share in 2018, growing at a CAGR of 12.6% and will cross USD 304,070.69 million by 2025

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn's disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 48.3% market share in 2018, growing at a CAGR of 12.1% and will cross USD 169,847.17 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 14.1% in the forecast period, and is expected to reach USD 84,577.41 million in 2025 from USD 25,259.88 million in 2017.

On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.9% market share in 2018, growing at a CAGR of 12.8% and will cross USD 351,807.22 million by 2025.

Questions? Ask to Our Experts @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-injectable-drug-delivery-market

On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 48.1% market share in 2018, growing at a CAGR of 13.0% and will cross USD 179,882.71 million by 2025.

On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 61.8% market share in 2018, growing at a CAGR of 12.9% and will cross USD 230,052.79 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 14.5% in the forecast period, and is expected to reach USD 79,428.60 million in 2025 from USD 22,963.21 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 71.0% market share in 2018, growing at a CAGR of 13.0% and will cross USD 266,909.52 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.0% in the forecast period, and is expected to reach USD 53,861.23 million in 2025 from USD 16,201.79 million in 2017.

Based on geography, the Europe injectable drug delivery market is segmented into geographical regions, such as,
- Germany
- United Kingdom
- France
- Spain
- Italy
- Russia
- Turkey
- Belgium
- Nether lands
- Switzerland
- Rest of Europe

Key market players for Europe injectable drug delivery market are listed below:

- Baxter International, Inc.,
- Becton Dickinson and Company,
- Gerresheimer AG,
- Pfizer, Inc.,
- Schott AG,
- Alkermes Plc.,
- Eli Lilly and Company,
- Sandoz,
- Terumo Corporation,
- Teva Pharmaceuticals Industries Ltd.
- Ypsomed,
- Bespak

Questions? We'll Put You On The Right Path Request Analyst Call: http://databridgemarketresearch.com/speak-to-analyst/?dbmr=europe-injectable-drug-delivery-market

Covered in this report

The report covers the present scenario and the growth prospects of the Europe injectable drug delivey market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

TABLE OF CONTENTS EUROPE INJECTABLE DRUG DELIVERY MARKET

1. INTRODUCTION

1.1. OVERVIEW OF EUROPE INJECTABLE DRUG DELIVERY MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. RISING CASES OF CHRONIC DISEASES
3.1.2. RISING DEMAND OF SELF-INJECTION DEVICES
3.1.3. GROWTH OF BIOLOGICS MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET

3.2. RESTRAINTS

3.2.1. NEEDLESTICK INJURIES AND INFECTIONS
3.2.2. HIGH COST OF DEVELOPMENT
3.2.3. STRICT REGULATORY FRAMEWORK

3.3. OPPORTUNITY

3.3.1. INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS

3.3.1.1. GENERICS
3.3.1.2. BIOSIMILARS

3.3.2. INCREASING DEMAND FOR CONTRACEPTIVE INJECTABLES

3.3.3. INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS

3.4. CHALLENGES

3.4.1. ALTERNATIVE ROUTE OF DRUG ADMINISTRATION
3.4.2. PRODUCT RECALL
3.4.3. STABILITY OF PRODUCTS
3.4.4. STERILITY OF INJECTIONS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. EUROPE INJECTABLE DRUG DELIVERY MARKET, REGULATORY

6.1. OVERVIEW
6.2. U.S. FDA APPROVAL
6.3. CE MARKING (EUROPEAN CONFORMITY)
6.4. EM (EUROPEAN MEDICINE AGENCY)

7. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY TYPE

7.1. OVERVIEW

7.2. INJECTABLE DRUG DELIVERY DEVICES

7.2.1. CONVENTIONAL INJECTION DEVICES
7.2.2. SELF INJECTION DEVICES
7.2.2.1. NEEDLE FREE INJECTORS (NFI)
7.2.2.2. AUTO INJECTORS
7.2.2.3. PEN INJECTORS
7.2.2.4. WEARABLE INJECTORS

7.3. INJECTABLE DRUG DELIVERY FORMULATION

7.3.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS

7.3.1.1. SOLUTIONS
7.3.1.2. RECONSTITUTED/LYOPHILIZED FORMULATIONS
7.3.1.3. SUSPENSIONS
7.3.1.4. EMULSIONS

7.3.2. NOVEL DRUG DELIVERY FORMULATIONS
7.3.2.1. COLLOIDAL DISPERSIONS
7.3.2.2. MICROPARTICLES
7.3.2.3. LONG ACTING INJECTION FORMULATION

8. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.1. OVERVIEW

8.2. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION

8.3. HORMONAL DISORDERS

8.3.1. INJECTABLE DRUGS FOR DIABETES
8.3.2. INJECTABLE DRUGS FOR ANEMIA
8.3.3. INJECTABLE DRUGS FOR REPRODUCTIVE HEALTH DISEASE
8.3.4. INJECTABLE DRUGS FOR ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5. INJECTABLE DRUGS FOR OSTEOPOROSIS
8.3.6. INJECTABLE DRUGS FOR GROWTH HORMONE DISORDERS (GHD)

8.4. ONCOLOGY

8.5. AUTOIMMUNE DISEASES
8.5.1. INJECTABLE DRUGS FOR RHEUMATOID ARTHRITIS
8.5.2. INJECTABLE DRUGS FOR MULTIPLE SCLEROSIS
8.5.3. INJECTABLE DRUGS FOR CROHN'S DISEASES
8.5.4. INJECTABLE DRUGS FOR PSORIASIS
8.5.5. INJECTABLE DRUGS FOR OTHER AUTOIMMUNE DISEASES

8.6. ORPHAN DISEASE

8.7. OTHER APPLICATIONS
8.7.1. INJECTABLE DRUGS FOR PAIN MANAGEMENT
8.7.2. INJECTABLE DRUGS FOR ALLERGY TREATMENT
8.7.3. INJECTABLE DRUGS FOR AESTHETIC TREATMENTS
8.7.4. INJECTABLE DRUGS FOR HEPATITIS C
8.7.5. INJECTABLE DRUGS FOR HEMOPHILIA

9. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN

9.1. OVERVIEW
9.2. CURATIVE CARE
9.3. IMMUNIZATIONS
9.4. OTHER USAGE PATTERN

10. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY MODE OF ADMINISTRATION

10.1. OVERVIEW
10.2. SKIN
10.3. CIRCULATORY/ MUSKOSKELETAL
10.4. ORGANS
10.5. CENTRAL NERVOUS SYSTEM

11. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END USER

11.1. OVERVIEW
11.2. HOSPITALS AND CLINICS
11.3. HOME HEALTHCARE SETTINGS
11.4. RESEARCH LABORATORIES
11.5. PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES
11.6. OTHER END USERS

12. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL

12.1. OVERVIEW
12.1.1. HOSPITAL PHARMACY
12.1.2. PHARMACY STORES
12.1.3. DIRECT TENDER
12.1.4. ONLINE PHARMACY

13. EUROPE INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY

13.1. OVERVIEW

13.2. EUROPE INJECTABLE DRUG DELIVERY MARKET

13.2.1. GERMANY INJECTABLE DRUG DELIVERY MARKET
13.2.2. FRANCE INJECTABLE DRUG DELIVERY MARKET
13.2.3. UK INJECTABLE DRUG DELIVERY MARKET
13.2.4. ITALY INJECTABLE DRUG DELIVERY MARKET
13.2.5. SWITZERLAND INJECTABLE DRUG DELIVERY MARKET
13.2.6. SPAIN INJECTABLE DRUG DELIVERY MARKET
13.2.7. NETHERLAND INJECTABLE DRUG DELIVERY MARKET
13.2.8. RUSSIA INJECTABLE DRUG DELIVERY MARKET
13.2.9. TURKEY INJECTABLE DRUG DELIVERY MARKET
13.2.10. BELGIUM INJECTABLE DRUG DELIVERY MARKET
13.2.11. REST OF EUROPE INJECTABLE DRUG DELIVERY MARKET

14. EUROPE INJECTABLE DRUG DELIVERY MARKET, COMPANY SHARE

14.1. COMPANY SHARE ANALYSIS: EUROPE

15. COMPANY PROFILES

15.1. BECTON, DICKINSON AND COMPANY

15.1.1. COMPANY OVERVIEW
15.1.1.1. DRIVERS EXPLAINED
15.1.1.2. WEAKNESSES EXPLAINED
15.1.1.3. OPPURTUNITIES EXPLAINED
15.1.1.4. THREATS EXPLAINED
15.1.2. PRODUCT PORTFOLIO
15.1.3. RECENT DEVELOPMENTS

15.2. PFIZER

15.2.1. COMPANY OVERVIEW
15.2.1.1. DRIVERS EXPLAINED
15.2.1.2. WEAKNESSES EXPLAINED
15.2.1.3. OPPURTUNITIES EXPLAINED
15.2.1.4. THREATS EXPLAINED
15.2.2. PRODUCT PORTFOLIO
15.2.3. RECENT DEVELOPMENTS

15.3. BAXTER INTERNATIONAL

15.3.1. COMPANY OVERVIEW
15.3.1.1. DRIVERS EXPLAINED
15.3.1.2. WEAKNESSES EXPLAINED
15.3.1.3. OPPURTUNITIES EXPLAINED
15.3.1.4. THREATS EXPLAINED
15.3.2. PRODUCT PORTFOLIO
15.3.3. RECENT DEVELOPMENTS

15.4. GERRESHEIMER AG

15.4.1. COMPANY OVERVIEW
15.4.2. PRODUCT PORTFOLIO
15.4.3. RECENT DEVELOPMENTS

15.5. SCHOTT AG INC.

15.5.1. COMPANY OVERVIEW
15.5.2. PRODUCT PORTFOLIO
15.5.3. RECENT DEVELOPMENTS

15.6. ALKERMES INC.

15.6.1. COMPANY OVERVIEW
15.6.2. PRODUCT PORTFOLIO
15.6.3. RECENT DEVELOPMENTS
15.7. ANTARES PHARMA
15.7.1. COMPANY OVERVIEW
15.7.2. PRODUCT PORTFOLIO
15.7.3. RECENT DEVELOPMENTS

15.8. BESPAK (SUBSIDIARY OF CONSORT MEDICAL COMPANY)

15.8.1. COMPANY OVERVIEW
15.8.2. PRODUCT PORTFOLIO
15.8.3. RECENT DEVELOPMENTS

15.9. ELCAM MEDICAL

15.9.1. COMPANY OVERVIEW
15.9.2. PRODUCT PORTFOLIO
15.9.3. RECENT DEVELOPMENTS

15.10. ELI LILLY AND COMPANY

15.10.1. COMPANY OVERVIEW
15.10.1.1. DRIVERS EXPLAINED
15.10.1.2. WEAKNESSES EXPLAINED
15.10.1.3. OPPURTUNITIES EXPLAINED
15.10.1.4. THREATS EXPLAINED
15.10.2. PRODUCT PORTFOLIO
15.10.3. RECENT DEVELOPMENTS

15.11. HASELMEIER

15.11.1. COMPANY OVERVIEW
15.11.2. PRODUCT PORTFOLIO
15.11.3. RECENT DEVELOPMENTS

15.12. MYLAN N.V.

15.12.1. COMPANY OVERVIEW
15.12.2. PRODUCT PORTFOLIO
15.12.3. RECENT DEVELOPMENTS

15.13. NOVO NORDISK

15.13.1. COMPANY OVERVIEW
15.13.2. PRODUCT PORTFOLIO
15.13.3. RECENT DEVELOPMENTS

15.14. OWEN MUMFORD LTD

15.14.1. COMPANY OVERVIEW
15.14.2. PRODUCT PORTFOLIO
15.14.3. RECENT DEVELOPMENTS
15.15. SANDOZ INTERNATIONAL GMBH
15.15.1. COMPANY OVERVIEW
15.15.2. PRODUCT PORTFOLIO
15.15.3. RECENT DEVELOPMENTS

15.16. SANOFI

15.16.1. COMPANY OVERVIEW
15.16.2. PRODUCT PORTFOLIO
15.16.3. RECENT DEVELOPMENTS

15.17. TERUMO CORPORATION

15.17.1. COMPANY OVERVIEW
15.17.2. PRODUCT PORTFOLIO
15.17.3. RECENT DEVELOPMENTS

15.18. TEVA PHARMACEUTICAL

15.18.1. COMPANY OVERVIEW
15.18.1.1. DRIVERS EXPLAINED
15.18.1.2. WEAKNESSES EXPLAINED
15.18.1.3. OPPURTUNITIES EXPLAINED
15.18.1.4. THREATS EXPLAINED
15.18.2. PRODUCT PORTFOLIO
15.18.3. RECENT DEVELOPMENTS

15.19. WEST PHARMACEUTICAL SERVICES, INC

15.19.1. COMPANY OVERVIEW
15.19.2. PRODUCT PORTFOLIO
15.19.3. RECENT DEVELOPMENTS

15.20. YPSOMED HOLDING AG

15.20.1. COMPANY OVERVIEW
15.20.2. PRODUCT PORTFOLIO
15.20.3. RECENT DEVELOPMENTS

16. RELATED REPORTS

Click Here to get customize report @ https://databridgemarketresearch.com/reports/europe-injectable-drug-delivery-market/

Related Report

Global Injectable Drug Delivery Market – Industry Trends and Forecast to 2024

Global Injectable Drug Delivery Market, By Type (Devices, Formulations), Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology), Usage Pattern (Curative Care, Immunizations), Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), End User, Geography – Industry Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com